Work

In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations

Year: 2019

Type: article

Abstract: Ibrexafungerp is a first-in-class glucan synthase inhibitor. In vitro activity was determined for 89 Candida glabrata isolates with molecularly identified FKS1 or FKS2 mutations conferring resistance to the echinocandins. All isolates were resistant to at least one echinocandin (i.e., anidulafungin, caspofungin, or micafungin) by broth microdilution. Results for ibrexafungerp were compared with those for each echinocandin.

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.01692-19

Authors: Natalie S. Nunnally, Kizee A. Etienne, David Angulo, Shawn R. Lockhart, Elizabeth L. Berkow

Institutions: Centers for Disease Control and Prevention, Scynexis (United States)

Language: English

Topic: Antifungal resistance and susceptibility

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2971516890